Hereditary pancreatitis

Last updated
Hereditary pancreatitis
Autosomal dominant - en.svg
This condition is inherited in an autosomal dominant manner

Hereditary pancreatitis (HP) is an inflammation of the pancreas due to genetic causes. It was first described in 1952 by Comfort and Steinberg [1] but it was not until 1996 that Whitcomb et al [2] isolated the first responsible mutation in the trypsinogen gene ( PRSS1 ) on the long arm of chromosome seven (7q35).

Contents

The term "hereditary pancreatitis" is used when a genetic biomarker is identified, and "familial pancreatitis" otherwise. [3]

Presentation

HP is characterised by attacks of epigastric pain, which are often associated with nausea and vomiting. Symptoms may start shortly after birth but onset varies periodically, with some patients not exhibiting symptoms until adulthood. There is usually progression to chronic pancreatitis with endocrine and exocrine failure and a mortally increased risk of pancreatic cancer. Lifetime risk of cancer has been variously calculated as 35–54% [4] [5] [6] to the age of 75 years and screening for early pancreatic cancer is being offered to HP sufferers on a scientific basis. [7] Some patients may choose to have their pancreas surgically removed to prevent pancreatic cancer from developing in the future. [8]

The epidemiology of HP follows a similar pattern to alcohol-associated chronic pancreatitis, but there are important differences. For example, HP typically has an earlier age of pancreatitis onset; although malabsorption and diabetes mellitus occur at a later stage in the disease progression. [5]

Genetics

The vast majority of the cases of HP are caused by substitutions, at base 365 (c.365G>A) and base 86 of the cDNA (c.86A>T) on the PRSS1 gene. The nucleotide substitutions were discovered in the late 1990s by classical linkage analysis [2] [9] and are now known as p.R122H and p.N29I respectively, according to the amino acid substitution and position in the protein sequence.

These mutations are rarely identified in general screens of patients with idiopathic disease [10] [11] [12] [13] and the phenotype of p.R122H and p.N29I is now well characterised [4] [5] [6] with the p.A16V mutation recently characterised for the first time. [14] There are many other rare mutations or polymorphisms of PRSS1 which remain less well understood [15] [16] and not all HP families have had the responsible genetic mutation identified.

The mechanism by which these genetic mutations cause pancreatitis is not yet known; but is likely to be the result of increased autoactivation [17] or reduced deactivation [18] of trypsinogen. However, a novel mechanism has recently been identified in a p.R116C kindred. [19]

Diagnosis

Families are defined as having HP, [5] if the phenotype is consistent with highly penetrant autosomal dominant inheritance. In simple terms, this would require two or more first degree relatives (or three or more second degree relatives) to have unexplained recurrent-acute or chronic pancreatitis in two or more generations. It is an autosomal dominant disease with penetrance that is generally accepted to be ≈80%. [1] [20]

Management

Treatment of HP resemble that of chronic pancreatitis of other causes. Treatment focuses on enzyme and nutritional supplementation, pain management, pancreatic diabetes, and local organ complications, such as pseudocysts, bile duct or duodenal obstruction.(PMC1774562)[ citation needed ]

Prognosis

A 2009 study which followed 189 patients found no excess mortality despite the increased risk of pancreatic cancer. [21]

Related Research Articles

<span class="mw-page-title-main">Pancreatitis</span> Inflammation of the pancreas

Pancreatitis is a condition characterized by inflammation of the pancreas. The pancreas is a large organ behind the stomach that produces digestive enzymes and a number of hormones. There are two main types: acute pancreatitis, and chronic pancreatitis.

<span class="mw-page-title-main">Pancreatic cancer</span> Type of endocrine gland cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

<span class="mw-page-title-main">Acute pancreatitis</span> Medical condition

Acute pancreatitis (AP) is a sudden inflammation of the pancreas. Causes, in order of frequency, include: a gallstone impacted in the common bile duct beyond the point where the pancreatic duct joins it; heavy alcohol use; systemic disease; trauma; and, in minors, mumps. Acute pancreatitis may be a single event; it may be recurrent; or it may progress to chronic pancreatitis.

<span class="mw-page-title-main">Chronic pancreatitis</span> Medical condition

Chronic pancreatitis is a long-standing inflammation of the pancreas that alters the organ's normal structure and functions. It can present as episodes of acute inflammation in a previously injured pancreas, or as chronic damage with persistent pain or malabsorption. It is a disease process characterized by irreversible damage to the pancreas as distinct from reversible changes in acute pancreatitis. Tobacco smoke and alcohol misuse are two of the most frequently implicated causes, and the two risk factors are thought to have a synergistic effect with regards to the development of chronic pancreatitis. Chronic pancreatitis is a risk factor for the development of pancreatic cancer.

Trypsinogen is the precursor form of trypsin, a digestive enzyme. It is produced by the pancreas and found in pancreatic juice, along with amylase, lipase, and chymotrypsinogen. It is cleaved to its active form, trypsin, by enteropeptidase, which is found in the intestinal mucosa. Once activated, the trypsin can cleave more trypsinogen into trypsin, a process called autoactivation. Trypsin cleaves the peptide bond on the carboxyl side of basic amino acids such as arginine and lysine.

<span class="mw-page-title-main">Hereditary nonpolyposis colorectal cancer</span> Autosomal dominant genetic condition associated with a high risk of cancer eg in the colon

Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is an autosomal dominant genetic condition that is associated with a high risk of colon cancer as well as other cancers including endometrial cancer, ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin. The increased risk for these cancers is due to inherited genetic mutations that impair DNA mismatch repair. It is a type of cancer syndrome. Because patients with Lynch syndrome can have polyps, the term HNPCC has fallen out of favor.

<span class="mw-page-title-main">Pancreaticoduodenectomy</span> Major surgical procedure involving the pancreas, duodenum, and other organs

A pancreaticoduodenectomy, also known as a Whipple procedure, is a major surgical operation most often performed to remove cancerous tumours from the head of the pancreas. It is also used for the treatment of pancreatic or duodenal trauma, or chronic pancreatitis. Due to the shared blood supply of organs in the proximal gastrointestinal system, surgical removal of the head of the pancreas also necessitates removal of the duodenum, proximal jejunum, gallbladder, and, occasionally, part of the stomach.

<span class="mw-page-title-main">Exocrine pancreatic insufficiency</span> Human disease

Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack or reduction of digestive enzymes made by the pancreas. EPI can occur in humans and is prevalent in many conditions such as cystic fibrosis, Shwachman–Diamond syndrome, different types of pancreatitis, multiple types of diabetes mellitus, advanced renal disease, older adults, celiac disease, IBS-D, IBD, HIV, alcohol-related liver disease, Sjogren syndrome, tobacco use, and use of somatostatin analogues.

Pancreatic diseases are diseases that affect the pancreas, an organ in most vertebrates and in humans and other mammals located in the abdomen. The pancreas plays a role in the digestive and endocrine system, producing enzymes which aid the digestion process and the hormone insulin, which regulates blood sugar levels. The most common pancreatic disease is pancreatitis, an inflammation of the pancreas which could come in acute or chronic form. Other pancreatic diseases include diabetes mellitus, exocrine pancreatic insufficiency, cystic fibrosis, pseudocysts, cysts, congenital malformations, tumors including pancreatic cancer, and hemosuccus pancreaticus.

<span class="mw-page-title-main">Phospholipid-transporting ATPase IC</span> Protein-coding gene in the species Homo sapiens

Probable phospholipid-transporting ATPase IC is an enzyme that in humans is encoded by the ATP8B1 gene. This protein is associated with progressive familial intrahepatic cholestasis type 1 as well as benign recurrent intrahepatic cholestasis.

<span class="mw-page-title-main">Microvillous inclusion disease</span> Medical condition

Microvillus inclusion disease, previously known as Davidson's disease, congenital microvillus atrophy and, less specifically, microvillus atrophy, is a rare genetic disorder of the small intestine that is inherited in an autosomal recessive pattern.

<span class="mw-page-title-main">Trypsin 1</span> Protein-coding gene in the species Homo sapiens

Trypsin-1, also known as cationic trypsinogen, is a protein that in humans is encoded by the PRSS1 gene. Trypsin-1 is the main isoform of trypsinogen secreted by pancreas, the others are trypsin-2, and trypsin-3 (meso-trypsinogen).

<span class="mw-page-title-main">SPINK1</span> Protein-coding gene in the species Homo sapiens

Pancreatic secretory trypsin inhibitor (PSTI) also known as serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) is a protein that in humans is encoded by the SPINK1 gene.

<span class="mw-page-title-main">Chymotrypsin-C</span> Protein-coding gene in the species Homo sapiens

Chymotrypsin C, also known as caldecrin or elastase 4, is an enzyme that in humans is encoded by the CTRC gene.

<span class="mw-page-title-main">Ductal cells</span>

Ductal cells refer to the epithelial cell lining of the pancreatic duct that deliver enzymes from the acinar cells to the duodenum. They have the essential function of producing bicarbonate-rich (HCO3-) secretion to neutralize stomach acidity. The hormone secretin stimulates ductal cells and is responsible for maintaining the duodenal pH and preventing duodenal injury from acidic chyme. Ductal cells mix their production with acinar cells to make up the pancreatic juice.

The European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC) was started by John Neoptolemos and colleagues in 1997 and has become the world’s most extensive study on hereditary pancreatic diseases. It enabled discovery of several genetic characteristics causative for hereditary pancreatitis and familial pancreatic cancer.

<span class="mw-page-title-main">Hereditary cancer syndrome</span> Inherited genetic condition that predisposes a person to cancer

A hereditary cancer syndrome is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancer and may also cause early onset of these cancers. Hereditary cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors.

Type 3c diabetes is diabetes that comes secondary to pancreatic diseases, involving the exocrine and digestive functions of the pancreas. It also occurs following surgical removal of the pancreas.

<span class="mw-page-title-main">HFE H63D gene mutation</span>

The HFE H63D is a single-nucleotide polymorphism in the HFE gene, which results in the substitution of a histidine for an aspartic acid at amino acid position 63 of the HFE protein (p.His63Asp). HFE participates in the regulation of iron absorption.

Garth David Ehrlich is a molecular biologist, genomic scientist, academic, and author who is most known for his development of the distributed genome hypothesis and bringing the biofilm paradigm to the field of chronic mucosal bacterial diseases. He is a professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University. He is also the founder and executive director of three Research Centers of Excellence: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms. In addition, he serves as the executive director of the Genomics Core Facility and the director of Molecular Pathology within Drexel Medicine Diagnostics and the Sidney Kimmel Cancer Center's Meta-omics Core Facility.

References

  1. 1 2 Comfort MW, Steinberg AG (May 1952). "Pedigree of a family with hereditary chronic relapsing pancreatitis". Gastroenterology. 21 (1): 54–63. doi:10.1016/S0016-5085(52)80120-9. PMID   14926813.
  2. 1 2 Whitcomb DC, Gorry MC, Preston RA, et al. (October 1996). "Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene". Nat. Genet. 14 (2): 141–5. doi:10.1038/ng1096-141. PMID   8841182. S2CID   21974705.
  3. Cheifetz, Adam S.; Brown, Alphonso; Curry, Michael; Alan C. Moss (2011-03-10). Oxford American Handbook of Gastroenterology and Hepatology. Oxford University Press US. pp. 223–. ISBN   978-0-19-538318-8 . Retrieved 9 August 2011.
  4. 1 2 Lowenfels AB, Maisonneuve P, DiMagno EP, et al. (March 1997). "Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group". J. Natl. Cancer Inst. 89 (6): 442–6. doi: 10.1093/jnci/89.6.442 . PMID   9091646.
  5. 1 2 3 4 Howes N, Lerch MM, Greenhalf W, et al. (March 2004). "Clinical and genetic characteristics of hereditary pancreatitis in Europe". Clin. Gastroenterol. Hepatol. 2 (3): 252–61. doi: 10.1016/S1542-3565(04)00013-8 . PMID   15017610.
  6. 1 2 Rebours V, Boutron-Ruault MC, Schnee M, et al. (January 2008). "Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series". Am. J. Gastroenterol. 103 (1): 111–9. doi:10.1111/j.1572-0241.2007.01597.x. PMID   18184119. S2CID   27464921.
  7. Greenhalf W, Grocock C, Harcus M, Neoptolemos J (2009). "Screening of high-risk families for pancreatic cancer". Pancreatology. 9 (3): 215–22. doi:10.1159/000210262. PMID   19349734. S2CID   29100310.
  8. Wolfgang, CL; Herman, JM; Laheru, DA; Klein, AP; Erdek, MA; Fishman, EK; Hruban, RH (Sep 2013). "Recent progress in pancreatic cancer". CA: A Cancer Journal for Clinicians. 63 (5): 322–323. doi:10.3322/caac.21190. PMC   3769458 . PMID   23856911.
  9. Gorry MC, Gabbaizedeh D, Furey W, et al. (October 1997). "Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis". Gastroenterology. 113 (4): 1063–8. doi: 10.1053/gast.1997.v113.pm9322498 . PMID   9322498.
  10. Chen JM, Piepoli Bis A, Le Bodic L, et al. (March 2001). "Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis". Clin. Genet. 59 (3): 189–93. doi:10.1034/j.1399-0004.2001.590308.x. PMID   11260229. S2CID   22717659.
  11. Lee KH, Yoon WJ, Ryu JK, Kim YT, Yoon YB, Kim CY (August 2004). "[Mutations of SPINK1 and PRSS1 gene in Korean patients with chronic pancreatitis]". Korean J Gastroenterol (in Korean). 44 (2): 93–8. PMID   15329520.
  12. O'Reilly DA, Yang BM, Creighton JE, Demaine AG, Kingsnorth AN (2001). "Mutations of the cationic trypsinogen gene in hereditary and non-hereditary pancreatitis". Digestion. 64 (1): 54–60. doi:10.1159/000048839. PMID   11549837. S2CID   21037146.
  13. Witt H, Luck W, Becker M (July 1999). "A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis". Gastroenterology. 117 (1): 7–10. doi:10.1016/s0016-5085(99)70543-3. PMID   10381903.
  14. Grocock CJ, Rebours V, Delhaye MN, et al. (March 2010). "The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families". Gut. 59 (3): 357–63. doi:10.1136/gut.2009.186817. PMID   19951905. S2CID   983450.
  15. Teich N, Rosendahl J, Tóth M, Mössner J, Sahin-Tóth M (August 2006). "Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis". Hum. Mutat. 27 (8): 721–30. doi:10.1002/humu.20343. PMC   2793115 . PMID   16791840.
  16. Szmola R, Sahin-Tóth M (May 2010). "Uncertainties in the classification of human cationic trypsinogen (PRSS1) variants as hereditary pancreatitis-associated mutations". J. Med. Genet. 47 (5): 348–50. doi:10.1136/jmg.2009.072751. PMC   2930840 . PMID   20452997.
  17. Sahin-Tóth M (June 2006). "Biochemical models of hereditary pancreatitis". Endocrinol. Metab. Clin. North Am. 35 (2): 303–12, ix. doi:10.1016/j.ecl.2006.02.002. PMC   1602208 . PMID   16632094.
  18. Felderbauer P, Schnekenburger J, Lebert R, et al. (August 2008). "A novel A121T mutation in human cationic trypsinogen associated with hereditary pancreatitis: functional data indicating a loss-of-function mutation influencing the R122 trypsin cleavage site". J. Med. Genet. 45 (8): 507–12. doi:10.1136/jmg.2007.056481. PMID   18511571. S2CID   24473962.
  19. Kereszturi E, Szmola R, Kukor Z, et al. (April 2009). "Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a novel disease mechanism". Hum. Mutat. 30 (4): 575–82. doi:10.1002/humu.20853. PMC   2663013 . PMID   19191323.
  20. Whitcomb DC (September 1999). "Hereditary pancreatitis: new insights into acute and chronic pancreatitis". Gut. 45 (3): 317–22. doi:10.1136/gut.45.3.317. PMC   1727629 . PMID   10446089.
  21. Rebours, Vinciane; Boutron-Ruault, Marie-Christine; Jooste, Valérie; Bouvier, Anne-Marie; Hammel, Pascal; Ruszniewski, Philippe; Lévy, Philippe (2009-09-01). "Mortality rate and risk factors in patients with hereditary pancreatitis: uni- and multidimensional analyses". The American Journal of Gastroenterology. 104 (9): 2312–2317. doi:10.1038/ajg.2009.363. ISSN   1572-0241. PMID   19550412. S2CID   2555617.